Table 1. Revised Multivariate Analysis of Associations Between Individual Comorbidities and Other Covariates With Post-Initial Therapy Mortality (288 Deaths Over 1 Year After Initial Therapy).
| Variables | HR (95% CI) | Assigned Score for AML-CM 2017 | P Value |
|---|---|---|---|
| Cardiac | 1.6 (1.1-2.2) | 1 | .01 |
| Diabetes | 1.1 (1.7-1.6) | 0 | .64 |
| Hepatic | 1.4 (1.0-1.8) | 1 | .04 |
| Infection | 1.3 (1.0-1.8) | 1 | .10 |
| Peptic ulcer | 1.4 (0.8-2.5) | 1 | .20 |
| Renal | |||
| Mild | 1.1 (0.8-1.7) | 0 | .51 |
| Moderate/severe | 1.0 (0.7-1.5) | 0 | .99 |
| Prior malignancy | 1.2 (0.9-1.6) | 0 | .25 |
| Heart valve disease | 1.5 (0.8-2.7) | 1 | .16 |
| Hyperlipidemia | 0.9 (0.7-1.3) | 0 | .68 |
| Hypertension | 1.1 (0.8-1.5) | 0 | .51 |
| Albumin, g/dL | |||
| <4-3.5 | 1.2 (0.9-1.7) | 0 | .28 |
| <3.5-3 | 1.3 (0.9-1.9) | 1 | .11 |
| <3.0 | 1.6 (1.1-2.5) | .03 | |
| Platelet count, ×103/µL | |||
| <100-50 | 1.0 (0.7-1.4) | 0 | .88 |
| <50-20 | 1.0 (0.7-1.4) | 0 | .94 |
| <20 | 1.2 (0.8-1.8) | 0 | .35 |
| LDH level, U/L | |||
| >200-500 | 1.7 (1.2-2.5) | 1 | .01 |
| >500-1000 | 1.8 (1.2-2.7) | 1 | .01 |
| >1000 | 2.4 (1.5-3.9) | 2 | <.001 |
| Sex | |||
| Male | 1.0 (0.8-1.3) | 0 | .73 |
| Female | 1.0 [Reference] | 0 | NA |
| Age, y | |||
| 0-49 | 1.0 [Reference] | 0 | NA |
| 50-59 | 1.7 (1.1-2.6) | 1 | .01 |
| 60-69 | 2.0 (1.3-3.0) | 2 | .002 |
| ≥70 | 2.5 (1.5-4.0) | 2 | <.001 |
| Cytogenetic/molecular risks per ELN 2017 | |||
| Favorable | 1.0 [Reference] | 0 | NA |
| Intermediate | 1.8 (1.2-2.8) | 1 | .01 |
| Adverse | 3.7 (2.4-5.7) | 3 | <.001 |
| Initial regimen intensity | |||
| Low | 1.6 (1.1-2.3) | NA | .02 |
| Intermediate | 1.0 [Reference] | NA | NA |
| High | 1.3 (0.9-1.9) | NA | .14 |
Abbreviations: AML-CM, acute myeloid leukemia composite model; ELN, European LeukemiaNet; HR, hazard ratio; LDH, lactate dehydrogenase; NA, not applicable.
SI conversion factors: To convert albumin to grams to per liter, multiply by 10; to convert LDH to microkatals per literal, multiply by 0.0167.